Announcements Trials

Browse Landscape

Phase

Status

Completed 14 Terminated 4 Recruiting 2 Not yet recruiting 2 Withdrawn 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 2 Neoplasms 1 Lymphoma, T-Cell 1 Lymphoma, B-Cell 1 Lymphoma 1 Esophageal Neoplasms 1 Breast Neoplasms 1

Interventions

Paclitaxel 28 Trastuzumab 22 Cyclophosphamide 21 Doxorubicin 14 Docetaxel 14 Carboplatin 11 exemestane 10 Radiotherapy 10 Letrozole 10 Capecitabine 10 pembrolizumab 8 Lapatinib 8 Fulvestrant 8 Neoadjuvant Therapy 6 Goserelin 6 Bevacizumab 6 Anastrozole 6 pertuzumab 5 palbociclib 5 eribulin 5 abemaciclib 5 Therapeutics 5 Magnetic Resonance Spectroscopy 5 Epirubicin 5 Chemotherapy, Adjuvant 5 Aromatase Inhibitors 5 tucatinib 4 Vinorelbine 4 Taxes 4 Tamoxifen 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Breast Neoplasms × entinostat × Clear all

NCT02115594 2014-10-08

ENCORE305

Syndax Pharmaceuticals

Phase 2 Withdrawn

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡